Prof. Dr. med. Johannes H. Schulte

Senior attending physician (“Geschäftsführender Oberarzt”)
Head of Pediatric Stem Cell Transplantation
Department of Pediatrics, Division of Oncology and Hematology
Charité - Universitätsmedizin Berlin
Augustenburger Platz 1
13353 Berlin
E-mail: maria.boehme(at)charite.de
Tel: +49 30 450 566 432

https://kinderonkologie.charite.de/en/research/schulte_group/

Scientific Scope

  • Understanding the biology of neuroblastoma     
  • Developing targeted and personalized treatment strategies for neuroblastoma

Our goal is the development of targeted and personalized treatment strategies and novel therapies for patients with neuroblastoma by combining multi-OMICs and wet lab techniques. Concepts identified in high-throughput analyses are validated in vitro and in vivo using cell culture model systems, patient-derived tumor xenografts (PDX) in immuno-deficient mice and genetically engineered mouse models (GEMMs). Our objective is to identify target structures of therapeutic relevance, to select promising compounds for pre-clinical evaluation and conduct early phase clinical trials.

Group Members

Dr. Falk Hertwig, Lab Head, Senior Scientist
Dr. Jörn Tödling, Senior bioinformatician
Dr. Filippos Klironomos, Senior bioinformatician
Dr. Steffen Fuchs, BIH Clinician Scientist
Annabell Szymansky, PhD Student
Mareike Bock, PhD Student

For all group members, please check our website

Selected References

  • Ackermann S, Cartolano M, Hero B, Welte A, Kahlert Y, Roderwieser A, Bartenhagen C, Walter E, Gecht J, Kerschke L, Volland R, Menon R, Heuckmann JM, Gartlgruber M, Hartlieb S, Henrich KO, Okonechnikov K, Altmüller J, Nürnberg P, Lefever S, de Wilde B, Sand F, Ikram F, Rosswog C, Fischer J, Theissen J, Hertwig F, Singhi AD, Simon T, Vogel W, Perner S, Krug B, Schmidt M, Rahmann S, Achter V, Lang U, Vokuhl C, Ortmann M, Büttner R, Eggert A, Speleman F, O'Sullivan RJ, Thomas RK, Berthold F, Vandesompele J, Schramm A, Westermann F*, Schulte JH*, Peifer M*, Fischer M*. A mechanistic classification of clinical phenotypes in neuroblastoma. Science. 2018 Dec 7;362(6419):1165-1170. doi: 10.1126/science.aat6768. PMID: 30523111
  • Henssen AG, Reed C, Jiang E, Garcia HD, von Stebut J, MacArthur IC, Hundsdoerfer P, Kim JH, de Stanchina E, Kuwahara Y, Hosoi H, Ganem NJ, Dela Cruz F, Kung AL, Schulte JH, Petrini JH, Kentsis A. Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors. Sci Transl Med. 2017 Nov 1;9(414); PMID: 29093183 7;362(6419):1165-1170. doi: 10.1126/science.aat6768. PMID: 30523111
  • Schramm A, Köster J, Assenov Y, Althoff K, Peifer M, Mahlow E, Odersky A, Beisser D, Ernst C, Henssen AG, Stephan H, Schröder C, Heukamp L, Engesser A, Kahlert Y, Theissen J, Hero B, Roels F, Altmüller J, Nürnberg P, Astrahantseff K, Gloeckner C, De Preter K, Plass C, Lee S, Lode HN, Henrich KO, Gartlgruber M, Speleman F, Schmezer P, Westermann F, Rahmann S, Fischer M, Eggert A, Schulte JH*. Mutational dynamics between primary and relapse neuroblastomas. Nat Genet 2015, Aug;47(8):872-7. PMID: 26121086
  • Heukamp LC, Thor T, Schramm A, De Preter K, Kumps C, De Wilde B, Odersky A, Peifer M, Lindner S, Spruessel A, Pattyn F, Mestdagh P, Menten B, Kuhfittig-Kulle S, Künkele A, König K, Meder L, Chatterjee S, Ullrich RT, Schulte S, Vandesompele J, Speleman F, Büttner R, Eggert A, Schulte JH*. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Science Transl Med 2012, 4:141ra9. PMID: 22764207
  • Molenaar JJ, Domingo-Fernández R, Ebus ME, Lindner S, Koster J, Drabek K, Mestdagh P, van Sluis P, Valentijn LJ, van Nes J, Broekmans M, Haneveld F, Volckmann R, Bray I, Heukamp L, Sprüssel A, Thor T, Kieckbusch K, Klein-Hitpass L, Fischer M, Vandesompele J, Schramm A, van Noesel MM, Varesio L, Speleman F, Eggert A, Stallings RL, Caron HN, Versteeg R, Schulte JH*. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nature Genet 2012, 44:1199-206. PMID: 23042116